Buprenorphine

CHEMBL511142 Phase 4 承認済み Small molecule
Half-Life
24-42 hours
Bioavailability
Protein Binding
Molecular Weight
467.6 g/mol
LogP
5.0
Phase
4

A partial opioid agonist used both for the treatment of opioid use disorder and for moderate-to-severe pain management. At lower doses, it suppresses opioid cravings and withdrawal symptoms while reducing the euphoric effects of other opioids. Its ceiling effect on respiratory depression makes it safer in overdose compared to full opioid agonists.

分子量

467.6430 g/mol

LogP

5.00

TPSA

62.20 Ų

リピンスキーの五則

適合

治療領域

薬物分類

作用機序

Partial mu-opioid receptor agonist and kappa antagonist with high receptor affinity.

Pharmacokinetics (PK)

Half-Life 24-42 hours

Pharmacodynamics (PD)

機序

Partial mu-opioid receptor agonist and kappa antagonist with high receptor affinity.

2D構造

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CO[C@@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5

InChI

InChI=1S/C29H41NO4/c1-25(2,3)26(4,32)20-15-27-10-11-29(20,33-5)24-28(27)12-13-30(16-17-6-7-17)21(27)14-18-8-9-19(31)23(34-24)22(18)28/h8-9,17,20-21,24,31-32H,6-7,10-16H2,1-5H3/t20-,21-,24-,26+,27-,28+,29+/m1/s1

Molecular Formula

C29H41NO4

HBD / HBA

2 / 5

回転可能結合数

5

重原子数

34

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

よくある質問

A partial opioid agonist used both for the treatment of opioid use disorder and for moderate-to-severe pain management. At lower doses, it suppresses opioid cravings and withdrawal symptoms while reducing the euphoric effects of other opioids. Its ceiling effect on respiratory depression makes it safer in overdose compared to full opioid agonists.

Partial mu-opioid receptor agonist and kappa antagonist with high receptor affinity.

Key pharmacokinetic parameters for Buprenorphine: Half-life: 24-42 hours.

Yes, Buprenorphine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

Related Drugs

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL511142. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 644073. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

医学的免責事項

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.